1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    





















































































































    Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions | American Journal of Neuroradiology  
    

















    





























    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleBrain

  
      

  
      
Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions
  
    	
S.-S. Lu, S.J. Kim, H.S. Kim, C.G. Choi, Y.-M. Lim, E.J. Kim, D.Y. Kim and S.H. Cho

  
    	
American Journal of Neuroradiology February 2014,  35 (2) 270-277; DOI: https://doi.org/10.3174/ajnr.A3677 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵


    1. Kuker  W, 
    2. Nagele  T, 
    3. Korfel  A, 
    4. et al
    . Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005;72:169–77
    CrossRefPubMed
  2. 2.↵


    1. Kawai  N, 
    2. Okubo  S, 
    3. Miyake  K, 
    4. et al
    . Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 2010;24:335–43
    CrossRefPubMed
  3. 3.↵


    1. Zacharia  TT, 
    2. Law  M, 
    3. Naidich  TP, 
    4. et al
    . Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008;18:411–17
    CrossRefPubMedWeb of Science
  4. 4.↵


    1. Buhring  U, 
    2. Herrlinger  U, 
    3. Krings  T, 
    4. et al
    . MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393–96
    CrossRef
  5. 5.↵


    1. Haldorsen  IS, 
    2. Espeland  A, 
    3. Larsson  EM
    . Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011;32:984–92
    Abstract/FREE Full Text
  6. 6.↵


    1. Haldorsen  IS, 
    2. Krakenes  J, 
    3. Krossnes  BK, 
    4. et al
    . CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989–2003. AJNR Am J Neuroradiol 2009;30:744–51
    Abstract/FREE Full Text
  7. 7.↵


    1. Erdag  N, 
    2. Bhorade  RM, 
    3. Alberico  RA, 
    4. et al
    . Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 2001;176:1319–26
    CrossRefPubMed
  8. 8.↵


    1. Lachenmayer  ML, 
    2. Blasius  E, 
    3. Niehusmann  P, 
    4. et al
    . Non-enhancing primary CNS lymphoma. J Neurooncol 2011;101:343–44
    CrossRefPubMed
  9. 9.↵


    1. Trendelenburg  G, 
    2. Zimmer  C, 
    3. Forschler  A, 
    4. et al
    . Atypical appearance of a primary central nervous system lymphoma. Arch Neurol 2006;63:908–09
    CrossRefPubMed
  10. 10.↵


    1. Given  CA  2nd., 
    2. Stevens  BS, 
    3. Lee  C
    . The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 2004;182:195–99
    CrossRefPubMedWeb of Science
  11. 11.↵


    1. Butzen  J, 
    2. Prost  R, 
    3. Chetty  V, 
    4. et al
    . Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000;21:1213–19
    Abstract/FREE Full Text
  12. 12.↵


    1. Majos  C, 
    2. Aguilera  C, 
    3. Alonso  J, 
    4. et al
    . Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009;30:544–51
    Abstract/FREE Full Text
  13. 13.↵


    1. Cianfoni  A, 
    2. Niku  S, 
    3. Imbesi  SG
    . Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007;28:272–77
    Abstract/FREE Full Text
  14. 14.↵


    1. Law  M, 
    2. Meltzer  DE, 
    3. Cha  S
    . Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 2002;44:986–89
    CrossRefPubMedWeb of Science
  15. 15.↵


    1. Malhotra  HS, 
    2. Jain  KK, 
    3. Agarwal  A, 
    4. et al
    . Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009;15:193–203
    Abstract/FREE Full Text
  16. 16.↵


    1. Raizer  JJ, 
    2. Koutcher  JA, 
    3. Abrey  LE, 
    4. et al
    . Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 2005;71:173–80
    CrossRefPubMed
  17. 17.↵


    1. Lange  T, 
    2. Dydak  U, 
    3. Roberts  TP, 
    4. et al
    . Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006;27:895–901
    Abstract/FREE Full Text
  18. 18.↵


    1. Yablonskiy  DA, 
    2. Neil  JJ, 
    3. Raichle  ME, 
    4. et al
    . Homonuclear J coupling effects in volume localized NMR spectroscopy: pitfalls and solutions. Magn Reson Med 1998;39:169–78
    CrossRefPubMed
  19. 19.↵


    1. Calli  C, 
    2. Kitis  O, 
    3. Yunten  N, 
    4. et al
    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403
    CrossRefPubMed
  20. 20.↵


    1. Balashov  KE, 
    2. Lindzen  E
    . Acute demyelinating lesions with restricted diffusion in multiple sclerosis. Mult Scler 2012;18:1745–53
    Abstract/FREE Full Text
  21. 21.↵


    1. Cha  S
    . Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279–89
    CrossRefPubMed
  22. 22.↵


    1. Cha  S, 
    2. Knopp  EA, 
    3. Johnson  G, 
    4. et al
    . Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29
    CrossRefPubMedWeb of Science
  23. 23.↵


    1. Cha  S, 
    2. Pierce  S, 
    3. Knopp  EA, 
    4. et al
    . Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001;22:1109–16
    Abstract/FREE Full Text
  24. 24.↵


    1. Bitsch  A, 
    2. Bruhn  H, 
    3. Vougioukas  V, 
    4. et al
    . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619–27
    Abstract/FREE Full Text
  25. 25.↵


    1. Horska  A, 
    2. Barker  PB
    . Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin North Am 2010;20:293–310
    CrossRef
  26. 26.↵


    1. Howe  FA, 
    2. Barton  SJ, 
    3. Cudlip  SA, 
    4. et al
    . Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223–32
    CrossRefPubMed
  27. 27.↵


    1. Tang  YZ, 
    2. Booth  TC, 
    3. Bhogal  P, 
    4. et al
    . Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768–77
    CrossRefPubMed
  28. 28.↵


    1. Soares  DP, 
    2. Law  M
    . Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009;64:12–21
    CrossRefPubMedWeb of Science
  29. 29.↵


    1. Sugie  M, 
    2. Ishihara  K, 
    3. Kato  H, 
    4. et al
    . Primary central nervous system lymphoma initially mimicking lymphomatosis cerebri: an autopsy case report. Neuropathology 2009;29:704–07
    CrossRefPubMed
  30. 30.↵


    1. Jahnke  K, 
    2. Schilling  A, 
    3. Heidenreich  J, 
    4. et al
    . Radiologic morphology of low-grade primary central nervous system lymphoma in immunocompetent patients. AJNR Am J Neuroradiol 2005;26:2446–54
    Abstract/FREE Full Text
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions
  
    	
S.-S. Lu, S.J. Kim, H.S. Kim, C.G. Choi, Y.-M. Lim, E.J. Kim, D.Y. Kim, S.H. Cho

  
    	
American Journal of Neuroradiology Feb 2014, 35 (2) 270-277; DOI: 10.3174/ajnr.A3677 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement